Infectologia

Miocardite após vacinação de adolescentes com BNT162b2 em Israel.

31 Jan, 2022 | 08:55h

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine

Conteúdos relacionados:

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Comentário no Twitter

Data from the Israeli MOH show estimates of myocarditis risk in the 21 days after a first & second dose of vaccine were 0.56 per 100,000 and 8.09 per 100,000 among male recipients and 0 per 100,000 and 0.69 per 100,000 among females. https://t.co/M6kxVA2toS pic.twitter.com/bQ4TBmcrj4

— NEJM (@NEJM) January 29, 2022

 

---

Consenso europeu | Prevenção da infecção articular periprotética na artroplastia total de quadril e de joelho.

31 Jan, 2022 | 08:42h

Prevention of Periprosthetic Joint Infection in Total Hip and Knee Replacement: One European Consensus – Journal of Clinical Medicine

---

M-A | Erradicação do Helicobacter pylori pode resultar em melhora modesta da dispepsia funcional.

31 Jan, 2022 | 08:31h

Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis – Gut (link para o resumo – $ para o texto completo)

Comentário: H. pylori eradication therapy may lead to better outcomes for functional dyspepsia – ACP Gastroenterology

---

Estudo randomizado | Imunoglobulina hiperimune não melhorou os desfechos de pacientes internados com COVID-19.

28 Jan, 2022 | 17:24h

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Comentários:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases

---

Características clínicas e desfechos de pacientes com síndrome da angústia respiratória aguda associada à COVID-19 submetidos a transplante de pulmão.

28 Jan, 2022 | 17:23h

Clinical Characteristics and Outcomes of Patients With COVID-19–Associated Acute Respiratory Distress Syndrome Who Underwent Lung Transplant – JAMA

Conteúdos relacionados: Cases of lung transplantation for Covid-19–related respiratory failure in the US were associated with a three-month survival of 95.6%.

---

Perspectiva | Em que ponto estamos com a Ômicron? Dados, cálculos, padrões e saída.

28 Jan, 2022 | 17:21h

Where do we stand with Omicron? – by Dr. Eric Topol

 

Comentário no Twitter

Where do we stand with Omicron?
I've summarized the new data, math, patterns, and potential exit ramphttps://t.co/SyCmCzkBQX @SubstackInc

— Eric Topol (@EricTopol) January 22, 2022

 

---

Estudo randomizado | Vacinação heteróloga de AD5-nCOV com CoronaVac vs. vacinação homóloga com CoronaVac.

28 Jan, 2022 | 17:20h

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial – Nature Medicine

Conteúdos relacionados:

RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination – Nature Medicine

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

---

Após a Ômicron, alguns cientistas preveem “um período de calmaria”.

28 Jan, 2022 | 17:19h

After Omicron, some scientists foresee ‘a period of quiet’ – Science

---

Perspectiva | A variante Ômicron tornará imune a maioria de nós?

28 Jan, 2022 | 17:18h

Will Omicron Leave Most of Us Immune? – The Atlantic

---

Uma segunda versão da variante Ômicron está se disseminando. Este é o motivo de os cientistas estarem alertas.

28 Jan, 2022 | 17:16h

A second version of omicron is spreading. Here’s why scientists are on alert – NPR

Ver também: Scientists Watch, Worry About New ‘Stealth’ Version of Omicron Variant – HealthDay

---